Wird geladen...
Early experience with remdesivir in SARS-CoV-2 pneumonia
At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients h...
Gespeichert in:
| Veröffentlicht in: | Infection |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Springer Berlin Heidelberg
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7229436/ https://ncbi.nlm.nih.gov/pubmed/32418190 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s15010-020-01448-x |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|